The pharmaceutical community is abuzz with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 receptor that’s demonstrating significant potential in clinical trials for treating obesity. Unlike some current weight loss approaches, retatrutide appears to offer a more substantial